In the last year, shares of Novartis (NVS) are down 14%. The company has been hit by a wave of patent expirations, and it’s become more difficult than expected to replace that revenue. The company reports third-quarter fiscal 2016 results on Tuesday.
Novartis was formed through the merger of Ciba-Geigy and Sandoz. Prescription pharmaceuticals accounted for about 62% of sales. Alcon vision care accounts for about 20% of revenue and Sandoz represents about 18%.
